A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Conditions: Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic Interventions: Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Other: Placebo Sponsors: NewAmsterdam Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials